The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Shavlovskaya O.A.

International University of Restorative Medicine», Moscow, Russia

Recognan (citicoline) prescribing in cerebrovascular diseases and type 2 diabetes mellitus patients

Authors:

Shavlovskaya O.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(9): 23‑27

DOI: 10.17116/jnevro202412409123

Read: 3607 times

Download PDF (RU)
Contact the author
Table of contents

RECOGNAN (CITICOLINE) PRESCRIBING IN CEREBROVASCULAR DISEASES AND TYPE 2 DIABETES MELLITUS PATIENTS
RECOGNAN (CITICOLINE) PRESCRIBING IN CEREBROVASCULAR DISEASES AND TYPE 2 DIABETES MELLITUS PATIENTS

To cite this article:

Shavlovskaya OA. Recognan (citicoline) prescribing in cerebrovascular diseases and type 2 diabetes mellitus patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(9):23‑27. (In Russ.)
https://doi.org/10.17116/jnevro202412409123

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Comparative study of cognitive impairment in subgroups of bipo­lar affe­ctive diso­rder types I and II, occu­rring with and without psychotic symptoms. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):7-11
Cognitive impairment in asthenic diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):27-32
Cognitive functions asse­ssment of elde­rly patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):46-50
Rela­tionship between stroke-associated pneumonia and long-term outcomes of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):57-61
Pote­ntial of animal-derived neuropeptides in complex therapy of diabetic neuropathy in patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):83-87
The main mechanisms of deve­lopment of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18
Differential diagnosis of Alzheimer’s disease and vascular cognitive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):26-35
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Prevalence of cere­brovascular diseases risk factors acco­rding to the cohort survey data in Bishkek, Kyrgyz Repu­blic. Russian Journal of Preventive Medi­cine. 2025;(3):34-39
Study of the levo­carnitine effi­cacy for the treatment of mode­rate cognitive impairment in patients with hype­rtension. Russian Journal of Preventive Medi­cine. 2025;(4):45-50
Abstract:

In a number of clinical studies, Recognan (citicoline) has demonstrated its effectiveness in patients with ischemic stroke, traumatic brain injury, cognitive disorders of various origins, in the complex therapy of asthenic and anxiety-depressive disorders, showing neuroprotective and neuropreparative properties. In recent years, emphasis has been placed on citicoline appointment in the complex therapy of patients with type 2 diabetes mellitus (DM2). In experimental (induced DM2) and clinical studies of patients with cerebrovascular diseases (CVD) and DM2, the effectiveness of Recogan (citicoline) against diabetic retinopathy and diabetic polyneuropathy in more significant clinical changes and negative dynamics absence of important laboratory parameters (blood glucose levels) in acute and stroke recovery periods in patients with DM2. The analysis of research materials allows Recogan to recommend to patients with CVD and DM2.

Keywords:

cerebrovascular diseases
cognitive impairment
diabetes mellitus
diabetic peripheral neuropathy
citicoline
Recognan

Authors:

Shavlovskaya O.A.

International University of Restorative Medicine», Moscow, Russia

Received:

06.08.2024

Accepted:

07.08.2024

Close metadata

References:

  1. Plataras C, Taskiris S, Angelogianni P. Effect of CDP-choline on brain acetylcholinesterase and Na+/K+-ATPase in adult rats. Clin Biochem. 2000;33:351-357.  https://doi.org/10.1016/s0009-9120(00)00084-9
  2. Secades J, Garery P. Citicoline: pharmacological and clinical review, 2022 update. Rev Neurol. 2022;75(s05):S1-S89.  https://doi.org/10.33588/rn.75s05.2022311
  3. Shavlovskaya OA, Bokova IA. Recognan (citicoline) efficacy and safety in cognitive impairment correction of various nosological forms. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(11):22-28. (In Russ.). https://doi.org/10.17116/jnevro202312311122
  4. Shavlovskaya OA. The assessment of the efficacy of citicoline in the early and recovery stages of stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(6):93-97. (In Russ.). https://doi.org/10.17116/jnevro20161166193-97
  5. Shavlovskaya OA. Recognan (citicoline) in the correction of asthenic and anxiety-depressive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(6):43-47. (In Russ.). https://doi.org/10.17116/jnevro202412406143
  6. Shavlovskaya OA, Bokova IA. Asthenic disorders correction with Recognan. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(3):57-62. (InRuss.). https://doi.org/10.17116/jnevro202412403157
  7. Ahlawat A, Sharma S. A new promising simultaneous approach for attenuating type II diabetes mellitus induced neuropathic pain in rats: iNOS inhibition and neuroregeneration. Eur J Pharmacol. 2018;818:419-428.  https://doi.org/10.1016/j.ejphar.2017.11.010
  8. Tyurenkov IN, Kurkin DV, Bakulin DA, et al. Cerebroprotective activity of metformin, gosogliptin, citicoline and a novel GPR119 agonist in cerebral ischemia under experimental diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(12-2):53-59. (In Russ.). https://doi.org/10.17116/jnevro201711712253-59
  9. Safavi M, Hosseini-Sharifabad A, Seyed-Yousefi Y, Rabbani M. protective effects of citicoline and benfotiamine each alone and in combination on streptozotocin-induced memory impairment in mice. Clin Psychopharmacol Neurosci. 2020;18(1):81-92.  https://doi.org/10.9758/cpn.2020.18.1.81
  10. Bogdanov P, Sampedro J, Solà-Adell C, et al. Effects of liposomal formulation of citicoline in experimental diabetes-induced retinal neurodegeneration. Int J Mol Sci. 2018;19(8):2458. https://doi.org/10.3390/ijms19082458
  11. García-López C, García-López V, Matamoros JA, et al. The role of citicoline and coenzyme Q10 in retinal pathology. Int J Mol Sci. 2023;24:5072. https://doi.org/10.3390/ijms24065072
  12. Liu Y, Li N, Ran X-W. Clinical effect of ligustrazine combined with citicoline for treatment of diabetic peripheral neuropathy. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008;28(7):606-609. 
  13. Bogolepova AN, Burd SG, Lebedeva AV, Kovalenko YeA. Opyt primeneniya tsitikolina u patsiyentov s postinsul’tnymi kognitivnymi narusheniyami. Nevrologiya, Neyropsikhiatriya, Psikhosomatika. 2020;12(4):43-48. (In Russ.). https://doi.org/10.14412/2074-2711-2020-4-43-48
  14. Voznyuk IA, Zavadenko NN, Kamchatnov PR, et al. The results of the round table: modern approaches to drug therapy of cognitive impairment in cerebrovascular pathology. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(8):147-152. (In Russ.). https://doi.org/10.17116/jnevro2021121081147
  15. Kuznetsova SM, Cherska MS. Clinical aspects of the use neuroprotectors in patients with chronic cerebrovascular diseases and diabetes mellitus. The Scientific Heritage. 2020;54-2(54):60-68. (In Russ).
  16. Bogolepova AN, Vasenina EE, Gomzyakova NA, et al. Clinical Guidelines for Cognitive Disorders in Elderly and Older Patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(10-3):6-137. (In Russ.). https://doi.org/10.17116/jnevro20211211036
  17. Cotroneo AM, Castagna A, Putignano S, et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin Interv Aging. 2013;8:131-137.  https://doi.org/10.2147/CIA.S38420
  18. Alvarez-Sabin J, Ortega G, Jacas C, et al. Long-term treatment with citicoline may improve poststroke vascular cognitive impairment. Cerebrovasc Dis. 2013;35(2):146-154.  https://doi.org/10.1159/000346602
  19. Cohen RA, Browndyke JN, Moser DJ, et al. Long-term citicoline (cytidine diphosphate choline) use in patients with vascular dementia: neuroimaging and neuropsychological outcomes. Cerebrovasc Dis. 2003;16(3):199-204.  https://doi.org/10.1159/000071116
  20. Shestakova MV, Alekhin DI, Kokorishvili MA, et al. Citicoline treatment in reconstructive operations of carotid arteries for prevention of reperfusion complications and cognitive disturbances in patients at risk. Neurological Journal. 2014;19(2):47-52. (In Russ.).
  21. Halushko OA. Neuroprotection in diabetic patients with acute stroke. Emergency Medicine. 2017;8(87):87-92. (In Russ.). https://doi.org/10.22141/2224-0586.8.87.2017.121329
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.